L.P. Shulman

E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer

Lori J. Goldstein, Anne O’Neill, JA Sparano et al. · Journal of Clinical Oncology · 2005 · 67 citations

Medicine, Oncology, Pharmacology +17

Mutant p53 protein in serum could be used as a molecular marker in human breast cancer

Gabriela Balogh, Daniel Mailo, P. Roncoroni et al. · International Journal of Oncology · 2006 · 56 citations · Full text

Medicine, Molecular Biology, Oncology +17

Abstract S1-07: Prognostic value of tumor-infiltrating lymphocytes (TILs) in two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199

Sylvia Adams, Ronan Gray, Sandra Demaria et al. · Cancer Research · 2013 · 15 citations

Medicine, Immunology, Oncology +17

Fatty acids and early human development

L.P. Shulman · Yearbook of Obstetrics Gynecology and Women s Health · 2008 · 14 citations

Life Sciences, Human Development, Nutritional Sciences +14